Blueberries Medical (BBM) AI Stock Analysis

• Market Cap: C$7.43M
• Dividend Yield: N/A
• Average Volume (3M): 5.76K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.54
• Revenue Growth: 55.74%
• EPS Growth: -27.59%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 495,090,100
• 10 Day Avg. Volume: 100
• 30 Day Avg. Volume: 5,759
• PEG Ratio: 0.06
• Price to Book (P/B): 4.78
• Price to Sales (P/S): 8.46
• P/FCF Ratio: -5.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: C$0.02 ▼(-25.00% Downside)

The score is primarily held down by weak financial performance driven by ongoing losses and worsening cash burn, despite improved gross margin and very low leverage. Technicals are mixed without clear positive momentum, and valuation support is limited due to negative earnings and no dividend yield.

Positive Factors

Gross margin improvement

Sustained gross margins near 31% indicate materially improved unit economics in cultivation and formulation. Durable margin expansion supports cash generation per unit sold, gives pricing flexibility versus peers, and underpins longer-term operating leverage if revenue growth resumes.

Low financial leverage

Very low debt reduces solvency and refinancing risk, preserving strategic optionality. With minimal leverage, management can prioritize investment in operations or R&D rather than servicing debt, which is a durable advantage while the company stabilizes cash flow.

Historical revenue scaling

Material revenue expansion through 2024 shows the business can scale cultivation, production and distribution capabilities. That structural growth history suggests operational capacity and market access exist to rebuild top-line momentum once margins and cash flow pressures are addressed.

Negative Factors

Large operating losses

Persistently large operating and net losses erode shareholders' capital and limit reinvestment capacity. Over a multi-month horizon this weakens competitive positioning, forces external financing, and delays a path to sustainable profitability unless cost structure or revenue mix changes materially.

Consistent negative cash flow and worsening burn

Ongoing negative operating and free cash flows increase liquidity and financing risk. Worsening cash burn means management must secure outside capital or curtail spending, constraining long-term investment and exposing the firm to funding stress if capital markets tighten over the next several months.

Declining equity and negative ROE

Falling equity and assets alongside sharply negative ROE signal value erosion and weakening balance-sheet resilience. This structural deterioration reduces the firm's ability to absorb shocks, undermines investor confidence, and can raise cost of capital for necessary future financing.

Blueberries Medical Business Overview & Revenue Model

Company Description

Blueberries Medical Corp. engages in the growth, cultivation, development, production, and supply of medicinal cannabis and related products in Colombia. It offers medicinal-grade cannabis oil extracts and related products. The company is headquartered in Bogotá, Colombia.

How the Company Makes Money

Blueberries Medical generates revenue primarily through the sale of its medical cannabis products to licensed distributors, pharmacies, and healthcare providers. The company has established key revenue streams from its cultivation operations, where it produces high-quality cannabis that is sold in bulk. Additionally, BBM generates income from its proprietary formulations and branded products, which are marketed directly to consumers through online platforms and retail partnerships. The company also benefits from strategic partnerships with healthcare institutions and research organizations, enabling it to explore new therapeutic applications and expand its market reach. Furthermore, BBM may engage in licensing agreements for its intellectual property, diversifying its income sources.

Blueberries Medical Financial Statement Overview

Summary

Blueberries Medical faces substantial challenges in achieving profitability and positive cash flow. Despite revenue growth, the company struggles with operational efficiency and cash generation. The balance sheet is stable with low leverage, but persistent losses and cash flow issues pose significant risks.

Income Statement

Blueberries Medical has shown some progress in revenue growth but continues to face significant profitability challenges. The gross profit margin has fluctuated but remains low, indicating efficiency issues. The net profit margin is negative, highlighting ongoing losses. Despite revenue growth, the EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet indicates a relatively stable equity position, although it has faced declining total assets over recent years. The debt-to-equity ratio is low, suggesting conservative leverage use. However, the return on equity is negative due to net losses, which is a concern. The equity ratio is healthy, showing good asset financing through equity.

Cash Flow

Cash flow analysis reveals significant negative operating cash flow and free cash flow, reflecting ongoing cash burn issues. The free cash flow to net income ratio is concerning, as it indicates inefficiencies in converting net income into cash. The operating cash flow to net income ratio is negative, showing issues in operational cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	413.97K	471.41K	288.27K	235.45K	138.75K	65.98K
Gross Profit	128.09K	164.52K	84.22K	-17.72K	-245.45K	62.40K
EBITDA	-1.44M	-1.04M	-1.22M	-811.47K	-4.05M	-4.11M
Net Income	-1.55M	-1.15M	-1.64M	-1.47M	-5.15M	-4.94M
Balance Sheet
Total Assets	1.18M	1.38M	2.42M	3.35M	3.59M	7.27M
Cash, Cash Equivalents and Short-Term Investments	23.81K	66.08K	818.16K	1.41M	1.34M	306.51K
Total Debt	11.02K	11.44K	12.80K	1.34M	1.44M	1.49M
Total Liabilities	409.76K	545.61K	470.72K	1.89M	2.16M	3.38M
Stockholders Equity	766.98K	834.81K	1.95M	1.47M	1.43M	3.89M
Cash Flow
Free Cash Flow	-1.31M	-796.85K	-1.35M	-1.47M	-1.73M	-3.00M
Operating Cash Flow	-1.31M	-796.85K	-1.33M	-1.47M	-1.68M	-2.39M
Investing Cash Flow	-3.76K	9.00K	382.92K	101.94K	-48.77K	-611.04K
Financing Cash Flow	1.05M	-1.95K	539.10K	1.35M	2.77M	783.92K

Blueberries Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.02, and above the 200-day MA of 0.01, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.07 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BBM.

Blueberries Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BBM	45 Neutral	C$7.43M	-4.05	-150.44%	―	55.74%	-27.59%
MVMD	44 Neutral	C$7.05M	-0.95	-148.48%	―	-46.59%	8.26%
CDVA	44 Neutral	C$3.84M	-1.33	―	―	1.60%	-213.10%
FFNT	39 Underperform	C$4.58M	-0.18	―	―	―	―
AYUR	38 Underperform	C$3.89M	-0.89	-271.33%	―	15.95%	-1.81%